Effects of Acetazolamide and CO2 Inhalation on Exercise-induced Periodic Breathing in Heart Failure

To evaluate the effects of CO2 inhalation and acetazolamide treatment on exercise-induced periodic breathing in patients with chronic stable heart failure.

Patients will be given CO2 (2%) during a constant workload exercise. Patients will be also evaluated by maximal cardiopulmonary exercise test without and with acetazolamide acute and chronic treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Heart Failure Behavior Cardiovascular Diseases Heart Diseases Heart Failure Motor Activity

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Centro Cardiologico Monzino, University of Milan

Milan, 20138, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

chronic heart failure in stable clinical condition
exercise-induced periodic breathing

Exclusion criteria

comorbidities
NYHA class IV

Treatment and study plan

Acetazolamide

Drug

i.v. 500 mg of acetazolamide for the acute study and 500 mg of acetazolamide p.o. t.i.d. for two days

Other names: Diamox

Primary outcomes

Suppression of periodic breathing

Time frame: two days

Secondary outcomes

suppression of sleeping apnea

Time frame: two days

Sponsors and collaborators

Lead sponsor

Centro Cardiologico Monzino

Other

Registry information

Important dates

Study start: 2007
Primary completion: 2011
Study completion: 2012
First posted: Aug 17, 2007
Registry last updated: Jan 28, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed